Updates are available Correction dated 2024-01-11

Article History

Received: 18 April 2023

Accepted: 7 September 2023

First Online: 28 November 2023

Change Date: 11 January 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00125-023-06083-3

Acknowledgements

: The expert technical assistance of W. Dolci, X. P. Berney, S. Gaspari, A. Strembitska (University of Lausanne, Lausanne, Switzerland) and V. D. T. Tran (Swiss Insititute of Bioinformatics, Lausanne, Switzerland) is gratefully acknowledged. We thank the Genomic Technologies Facility of the University of Lausanne (Lausanne, Switzerland) for generating the snRNA-seq data and the Protein Analysis Facility from the University of Lausanne for the synaptosomal proteomic analysis. Some of the data were presented as an abstract at the 58th Annual Meeting of the EASD in 2022.

: All transcriptomic data are available via the GEO (ExternalRef removed), using the accession no. GSE226277. Proteomic data are available via the ProteomeXchange data repository (ExternalRef removed), using the accession no. PXD040183.

: Open access funding provided by University of Lausanne This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU), under grant agreement number 777460 (HypoRESOLVE). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and the EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF) and The Leona M and Harry B Helmsley Charitable Trust. The project was also supported by grants to BT from the Swiss National Science Foundation (310030–182496) from the European Research Council Advanced Grant (INTEGRATE, No. 694798).

: JC-A was, and CF is employed by Novo Nordisk. The authors report no industry links or other personal connections. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: JC-A participated in the study design, performed all the animal experimentations, prepared the nuclei for RNA-seq analysis and the synaptosomal fractions for proteomic analysis, analysed and interpreted the data, and wrote the paper. ARS-A participated in the study design, analysed the RNA-seq data and critically reviewed the paper. CF helped develop the mouse model, interpret the physiology data and corrected the manuscript. FM analysed the RNA-seq data, prepared the illustrations and wrote the paper. ME, AM and RJM contributed to the design of the experimental protocol and to the interpretation of the data, and critically reviewed the manuscript. MI contributed to the study design, data interpretation and writing the paper. BT conceived the study and supervised its execution, interpreted the data and wrote the paper. All authors commented on the paper and approved its final content. BT is the guarantor of this work.